WTR: EXOZ 2Q26 update - from platform validation to commercial execution
investorpress clippingsNCT
WTR: EXOZ 2Q26 update - from platform validation to commercial executionAugust 25, 2026
Q&A: Tyler Korman, Michael Heltzen, Damien Perriman
heltzeninvestorvideoperrimankorman
Transcript: Q2 2026 investor update from EXOZAugust 21, 2026
Q2 2026 investor update
heltzenpress releaseinvestor
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET todayAugust 20, 2026
NCT process advances beyond original commercial-scale economic targets
press releaseinvestorscienceperrimanNCT
eXoZymes' NCT process achieves 10-fold productivity increase, advancing beyond original commercial-scale economic targetsAugust 18, 2026
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM Eastern
press releaseinvestor
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM EasternAugust 11, 2026
EXOZ and LBNL awarded Genesis Mission grant from DOE
heltzenpress releasescience
eXoZymes selected for DoE’s Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturingJuly 23, 2026
Webull 'Biotech Sector' webinar by Perriman
investorpress clippingsvideopodcastperriman
Webull: 'Biotech Sector' webinar by Damien PerrimanJune 30, 2026
Biomass Magazine
biofuelmedicinepress clippingsscience
Biomass Magazine: Why Use Living Cells? NLR Is Making Chemicals With Enzymes AloneJune 29, 2026
Bionity.com
press clippingscannabinoids
Bionity.com: EXOZ awarded $2M NIH grant to advance cannabinoid analogues for drug discoveryJune 26, 2026
PRISM MarketView
press clippingscannabinoids
PRISM MarketView: NIH Cash Fuels eXoZymes’ Push Into Next‑Gen CannabinoidsJune 25, 2026
Previous page
Page 1 of 15
Next page